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Article

Structure-based redesign of lysostaphin yields potent
antistaphylococcal enzymes that evade immune cell surveillance
Kristina Blazanovic1, Hongliang Zhao1,2, Yoonjoo Choi3, Wen Li1, Regina S Salvat1, Daniel C Osipovitch4, Jennifer Fields5,
Leonard Moise6, Brent L Berwin5,7, Steven N Fiering5,7, Chris Bailey-Kellogg3 and Karl E Griswold1,7,8

Staphylococcus aureus infections exert a tremendous burden on the health-care system, and the threat of drug-resistant strains
continues to grow. The bacteriolytic enzyme lysostaphin is a potent antistaphylococcal agent with proven efficacy against both
drug-sensitive and drug-resistant strains; however, the enzyme’s own bacterial origins cause undesirable immunogenicity and pose
a barrier to clinical translation. Here, we deimmunized lysostaphin using a computationally guided process that optimizes sets of
mutations to delete immunogenic T cell epitopes without disrupting protein function. In vitro analyses showed the methods to be
both efficient and effective, producing seven different deimmunized designs exhibiting high function and reduced immunogenic
potential. Two deimmunized candidates elicited greatly suppressed proliferative responses in splenocytes from humanized mice,
while at the same time the variants maintained wild-type efficacy in a staphylococcal pneumonia model. Overall, the deimmunized
enzymes represent promising leads in the battle against S. aureus.
Molecular Therapy — Methods & Clinical Development (2015) 2, 15021; doi:10.1038/mtm.2015.21; published online 17 June 2015

INTRODUCTION
Staphylococcus aureus causes a range of potentially life-threatening
infections including skin lesions,1 lung infections,2 bacteremia,3 ocular infections, and endocarditis.4 In 2009 alone, there were 697,248
S. aureus associated hospitalizations, a full two-third of which were
caused by methicillin-resistant S. aureus (MRSA).5 MRSA causes more
than 11,000 deaths in the United States each year,6 and it is now common among both hospital-associated and community-associated
infections. A 2012 estimate puts the cost of community associated MRSA alone at $1–13 billion annually.7 In addition to the high
clinical incidence of MRSA,8 S. aureus resistance to other antibiotics
is on the rise.9 The enormous financial and human costs of drugresistant S. aureus infections has prompted both the CDC and
WHO to highlight this threat and call for new treatment options.6,10
However, technical constraints and economic concerns have stymied antibiotic development pipelines. Moreover, seven decades of
experience has shown that bacterial pathogens begin developing
resistance to new chemotherapies within a few years of their initial
use.11 Therefore, addressing this medical need in a comprehensive
fashion will require more careful antibiotic stewardship combined
with a search for novel and more robust therapeutic agents.
As opposed to further elaboration of small molecule chemotherapies, there is mounting evidence that bacteriolytic enzymes represent a powerful new class of antibacterial agents.12–14 Staphylococcus

simulans lysostaphin (LST) is a highly effective, two-domain antistaphylococcal bacteriocin that efficiently kills both drug-sensitive
and drug-resistant S. aureus. LST efficacy has been demonstrated
in a wide range of in vitro studies, in vivo studies, and even human
trials.15 Because of its own bacterial origins, however, LST drives a
potent immune response in animals and humans. LST-antibody
immune complexes are thought to cause toxicity in numerous models, including nonhuman primates.15 Thus, immunogenicity represents a serious barrier to LST clinical translation, and developing
deimmunized variants would reduce associated health risks, facilitate clinical testing and approval, and ultimately enable repeated
use in individuals requiring multiple treatment cycles.
To address the issue of LST immunogenicity, we sought to capitalize on a detailed understanding of cellular and molecular processes that underlie development of antidrug antibodies. Immune
surveillance of biotherapeutics begins with internalization of a
protein drug by antigen-presenting cells. These cells process the
protein into short peptide fragments, putative immunogenic
sequences are bound by class II major histocompatibility complex
proteins (MHC II, also known as HLA in humans), and the complexes are trafficked to the cell surface where they are interrogated
by CD4+ helper T cells.16 Bona fide immunogenic peptides, termed
T cell epitopes, mediate formation of ternary MHC-peptide-T cell
receptor complexes. The result of this cell–cell interaction is a
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Figure 1 Epitope map of wild-type LSTCAT catalytic domain and positions of deimmunizing mutations. A map of predicted epitopes in wild type LSTCAT
is shown as a bar plot, where amino acid positions are indicated on the x-axis and the number of MHC II alleles predicted to bind a given nonamer
peptide are shown on the y-axis. Epitopes are indicated by bars at the first residue of the nonamer peptide. Epitopes cluster into five distinct regions
shown as purple, blue, green, orange, and red bars, respectively. The positions of deimmunizing mutations are indicated with black triangles on the
x-axis, and wild type residues are noted in red text. The mutational compositions of the seven characterized variants are shown below in black text,
and the fraction of putative epitopes deleted by each mutation is indicated in parenthesis next to the mutant residue (i.e., “3/10” indicates deletion of
3 out of 10 putative epitopes in that cluster).

complex signaling cascade that drives T cell stimulation, B cell
maturation, and ultimately production of class-switched IgG antibodies that bind the offending biotherapeutic with high specificity and affinity.17 Formation of antidrug antibodies may therefore
be circumvented by engineering proteins so as to prevent molecular recognition of constituent peptides, a process termed T cell
epitope deletion.18,19
LST is a two domain protein, with an N-terminal glycylglycine
zinc endopeptidase domain (LSTCAT ) and a C-terminal SH3-like cell
wall binding domain (LSTBD). This modular architecture, which is a
common feature of many lytic enzymes,13,20 enables mix and match
construction of chimeric cell wall hydrolases from natural catalytic
and cell wall binding domains.21–26 Prompted by the modular nature
of staphylolytic enzymes, we elected to pursue aggressive deimmunization of the LSTCAT domain only, leaving the native LSTBD domain
intact. We anticipated that a globally deimmunized catalytic
domain would have broad utility as a fusion partner to any number
of different bacterial targeting moieties, including both native and
engineered cell wall binding domains.
In order to deimmunize LSTCAT, we applied the EpiSweep protein
design algorithm27 to simultaneously optimize variants for two competing objective functions: low immunogenic potential (assessed
via predicted T cell epitope content) and retention of molecular fitness (assessed via molecular mechanics energies). Variants whose
predicted immunogenicities and molecular energies are not simultaneously dominated by any other single enzyme represent the
Pareto optimal frontier of the protein design space.28 EpiSweep
generates all such Pareto optimal variants along with successively
sub-optimal designs,27 thereby enabling the selection of diverse
candidates meriting experimental evaluation. A small panel of engineered LSTCAT designs was selected, produced, and evaluated using
Molecular Therapy — Methods & Clinical Development (2015) 15021

both in vitro and in vivo assays of molecular function and immunogenicity. The results demonstrate efficient and effective production
of deimmunized yet highly functional LST variants, some of which
may ultimately prove useful in combatting MRSA and other dangerous S. aureus infections.
RESULTS
A predictive analysis identified putative T cell epitopes clustered
throughout the LSTCAT sequence (Figure 1). To address this immunogenicity risk, deimmunized LST variants were rapidly generated
in a closed-loop engineering process that tightly coupled computational design and experimental analysis. Stage one narrowed the
pool of prospective deimmunizing mutations to a functionally validated subset (Figure 2, left), and stage two integrated these individual mutations into globally deimmunized LSTCAT designs (Figure 2,
right). In a subsequent third stage, the most promising lead candidates were more rigorously characterized, including assessment of
in vivo efficacy and immunogenicity in humanized mice. Detailed
results from each stage of the process follow.
Stage 1: design and deimmunization priors
At the time of these studies, there was no available LSTCAT crystal or
NMR structure, and a homology model was therefore constructed
using the crystal structure of the homologous enzyme LytM29
(Figure 2a,d inset). Overall, the LSTCAT and LytM sequences aligned
closely, and there was a well-matched loop model for the one
small region of LSTCAT that lacked a template segment in the LytM
structure. As a result, the energy minimized model appeared to be
of very high quality, attaining a QMEAN score of 0.63 (within the
0.6–0.7 range typical of high resolution crystal structures).30
© 2015 The American Society of Gene & Cell Therapy
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Figure 2 Two stage computationally-driven development of LSTCAT variants: Stage 1-left; stage 2-right. A structural map of putative LSTCAT epitope
content bridges the Design Priors for both stages. Thick red tubes indicate dense, overlapping MHC II binding peptides, and thin white tubes indicate
no predicted MHC II binding. (a) Priors for the initial design calculations identified allowed mutations based on their frequencies in a multiple sequence
alignment of LSTCAT homologs, represented here as a logo plot. (b) Initial EpiSweep calculations generated an undominated Pareto optimal frontier,
and near-optimal frontiers, at each mutational load. Mutational loads are: red = 8, blue = 7, purple = 6, green = 5, orange = 4, dark blue = 3, yellow = 2,
black = wild type. X-axis is reduction in predicted epitope content and y-axis is computed molecular energy in arbitrary units, with wild type reference
at 0. (c, top) Characterization of 15 individual point mutations that appeared frequently in designs from b. Expression level is shown in blue on left
y-axis and specific lytic activity towards S. aureus in green on the right y-axis. (c, bottom) Predicted number of epitopes deleted by each point mutation.
Validated substitutions selected for stage 2 protein design are highlighted in green boxes. (d) Priors for stage 2 design calculations were constrained
to twelve specific mutations validated in c. Mutation S122D was included in all designs. (e) Final EpiSweep calculations generated a new set of Pareto
optimal and near-optimal designs at mutational loads of 2–8 per enzyme, and fourteen candidates were selected for experimental analysis (indicated as
filled diamonds). (f, top) Functional characterization of seven high expressing constructs. Apparent melting temperature is shown in purple on the left
y-axis, and specific lytic activity in green on the right y-axis. (f, bottom) Measured MHC II binding for the seven engineered variants. Five corresponding
constituent peptides from each LST design were evaluated for binding to eight different human MHC II proteins. Peptides were categorized as strong
– red (IC50 < 0.1 µmol/l), moderate – orange (0.1 µmol/l ≤ IC50 < 1 µmol/l), weak – yellow (1 µmol/l ≤ IC50 < 10 µmol/l), or nonbinders (IC50 ≥ 10 µmol/l),
and total counts of binders are shown for each variant. Variants F4a and F8a, highlighted in green boxes, were chosen for further analysis.

Computational methods, such as the EpiMatrix epitope predictor31 used here, enable efficient analysis of epitopes in the wild-type
sequence, as well as optimization of possible mutations for epitope
© 2015 The American Society of Gene & Cell Therapy

deletion. The wild type LSTCAT domain, previously engineered to
delete an N-linked glycosylation sequon,32 was predicted to contain 21 nonamer peptides having 50 cumulative MHC II binding
Molecular Therapy — Methods & Clinical Development (2015) 15021
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interactions with the eight most common MHC II alleles (Figure 1).
The majority of putative epitopes clustered into five distinct regions
(named C1WT to C5WT), two of which exhibited dense, overlapping,
and highly promiscuous MHC II binding (Supplementary Figure S1,
clusters C2WT and C5WT). These epitope hotspots were distributed
throughout the LSTCAT molecular structure (Figure 2a,d inset).
In stage 1, prospective deimmunizing mutations were limited to
a set of 36 amino acid substitutions at 20 different residue positions.
The allowed mutations were identified based on frequency in a set
of diverse LSTCAT homologs (Figure 2a), constraining that subset to
avoid known detrimental mutations, avoid active site residues, and
require deletion of at least one putative epitope.
Initial computational designs
Based on the deimmunization priors, EpiSweep generated a total
of 1,663 designs having two to eight mutations each. The protein
plans mapped a Pareto optimal frontier in the two-dimensional
energy score versus epitope score design space, and the design
set also included 19 near-optimal frontiers at each mutational load
(Figure 2b). As seen in the graphic, increased aggressiveness in
deleting epitopes (lower epitope score) requires an increased energetic penalty higher energy score), though many of the designs
have better predicted energy than wild type, and no penalty is particularly severe. As is typically observed, higher mutational loads
(left most sets of frontiers) leverage combinations of mutations
to achieve a desired reduction in epitope content, and relative to
aggressive single mutations, these combinations incur a smaller
energetic penalty. Conversely, to achieve a given epitope score at
lower mutational loads, each mutation must delete a larger relative
number of epitopes, and these more aggressive substitutions tend
to have a greater energetic cost. Compare, for example, the energies of designs having identical epitope scores but four mutations
(in orange) versus eight mutations (in red) (Figure 2b).
Functional analysis of point mutants
While the ultimate goal was production of integrated m
 ulti-mutation
variants, we first sought to quickly identify and eliminate detrimental
mutations that individually undermined expression or activity. The
15 mutations appearing most frequently among the initial designs
were individually introduced into the aglycosylated w
 ild-type
LST backbone.32 Mutant genes were cloned into Pichia pastoris,
expressed on a small scale, and LST activities and expression levels
were determined by analysis of crude culture supernatants. Based
on densitometry of polyacrylamide gels (Supplementary Figure S2),
10 variants had expression yields greater than or equal to 90%
wild type, with only 2 variants exhibiting less than 70% wild type
expression (Figure 2c, variants R118T = 47% and S124Y = 35%). Lytic
activities towards S. aureus strain SA113 were quantified using a
fluorometric kinetic assay, and rates were normalized to estimated
expression levels. Thirteen of 15 variants had estimated specific
activities equal to or greater than wild type (Figure 2c). The two
exceptions, variants F38G and S124Y, experienced 30 and 84% rate
reductions, respectively.
Stage 2: deimmunization priors
According to the stage 1 functional analysis (Figure 2c), F38G and
S124Y were deemed detrimental and excluded from future designs.
Mutation S122G, although fully functional, was also excluded, as it
targeted the same epitope cluster as S122D but did so less effectively (deleting only 3 putative epitopes as opposed to a net of 10,
Molecular Therapy — Methods & Clinical Development (2015) 15021

respectively, Figure 2c and Supplementary Figure S1). Given the fact
that S122D was a particularly efficient epitope silencer (Figure 2c
and Supplementary Figure S1), it was specifically incorporated into
all stage 2 plans. Thus stage 2 design considered 11 prospective
mutations (in addition to S122D): N12G, N13H, I41E, K46H, L83M,
Y93H, K95E, I99Q, R118T, N121G, and S124G (Figure 2d).
Lead computational designs
Based on this more restricted set of prospective deimmunizing
mutations, EpiSweep was again implemented to generate Pareto
optimal frontiers and near-optimal frontiers. It optimized a total of
1,400 variants with mutational loads from two to eight (Figure 2e).
With the reduced pool of candidate mutations, there was less distinction between the curves for different mutational loads, but the
same trade-off between deimmunizing aggressiveness and energetic penalty was observed.
Prior to candidate selection, each of the designs was subjected
to global energy minimization, allowing both side chains and
backbone atoms to relax. Fourteen low energy designs at mutational loads of two to eight were selected for experimental analysis
(Supplementary Table S1). Among selected designs, predicted epi
tope scores ranged from 36 to 24, corresponding to a 28–52% reduction in epitope content relative to wild type (epitope score = 50).
Functional analysis of globally deimmunized variants
The 14 chosen designs were cloned, expressed, purified, and subjected to preliminary analysis (Supplementary Table S1). Seven of
the 14 variants expressed at reasonable levels (≥30% wild type), and
apparent melting temperatures for these enzymes ranged from 89
to 99% that of wild-type LST (Figure 2f). The activity of the seven
designs was assessed using a fluorometric kinetic assay of bacterial
lysis, and all variants maintained specific lytic rates greater than 50%
that of wild type (Figure 2f). Overall, the engineered designs exhibited good thermostability and high levels of antibacterial activity,
despite having as many as eight mutations in the catalytic domain.
Interestingly, the seven designs that initially failed to express all
encoded the R118T mutation, which by itself had resulted in a 50%
reduction in expression levels (Figure 2c). Reversion of this single
mutation restored expression in all seven associated designs, and
the seven reverted variants were all found to have good activity
and stability (Supplementary Table S1). Thus, 80% of the prospective deimmunizing mutations selected by EpiSweep in stage 1 produced stable and functional enzymes when combined as integrated
designs, although preanalysis as individual point mutations was
a key step in rapidly eliminating deleterious substitutions (F38G,
S124Y, and in hindsight, R118T).
Immunoreactivity by peptide-MHC II binding assays
To deimmunize a biotherapeutic agent, the EpiSweep algorithm seeks
to disrupt class II MHC binding of peptide fragments derived from the
protein. As a measure of success, competition binding assays33 were
performed with recombinant human MHC II, known peptide antigens, and LSTCAT peptide fragments. Peptides representing wild-type
LSTCAT epitope clusters (Supplementary Figure S1) were synthesized,
as were cognate peptides derived from each of the seven successfully
expressed designs from Supplementary Table S1. Peptide affinities for
MHC II proteins were categorized as either strong (IC50 < 0.1 μmol/l),
moderate (0.1 μmol/l ≤ IC50 < 1 μmol/l), weak (1 μmol/l ≤ IC50 < 10
μmol/l), or nonbinders (IC50 ≥ 10 μmol/l). High-affinity interaction
between peptide antigens and class II MHC is a key determinant of
© 2015 The American Society of Gene & Cell Therapy
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Table 1

Detailed performance analysis of deimmunized LST designsa
MIC (µg/ml)

Design
ID

%WT
lytic rate

Tm
(°C)

Strain 1
SA113

Strain 2
6445

Strain 3
3425-1

Strain 4
3425-3

Wild type

100 ± 30

59.0 ± 0.4

0.02 ± 0.00

0.03 ± 0.01

0.04 ± 0.02

0.03 ± 0.02

Commercial

60 ± 20

47.3 ± 0.4

0.03 ± 0.00

0.03 ± 0.00

0.04 ± 0.01

0.03 ± 0.00

F4a

70 ± 30

55.8 ± 0.2

0.02 ± 0.01

0.06 ± 0.04

0.11 ± 0.09

0.05 ± 0.03

F8a

60 ± 20

52.8 ± 0.3

0.04 ± 0.01

0.13 ± 0.07

0.2 ± 0.1

0.2 ± 0.1

LST, Staphylococcus simulans lysostaphin; MIC, minimal inhibitory concentration.
a
Errors are standard deviation from a minimum of biological duplicates measured in triplicate.

subsequent T cell immunogenicity,34–36 and all five wild-type LST peptides exhibited submicromolar IC50’s for at least one human MHC II
protein (Supplementary Table S2). Peptides C3WT, C4WT, and C5WT
proved to be promiscuous tight binders, each exhibiting high-affinity
interactions with three to four MHC II alleles.
The peptide-MHC II binding analysis included a total 26 peptides
and eight MHC II alleles yielding 208 separate affinity determinations. Of the 168 pairs of wild-type and cognate deimmunized
affinities, there were 63 instances in which the deimmunizing
mutations reduced affinity by greater than 10-fold and/or ablated
binding entirely (i.e., IC50 > 250 μmol/l, Supplementary Figure S3).
There were another 13 cases in which the mutation reduced binding by 5- to 10-fold. In contrast, there were only 14 examples of
>10-fold enhanced binding by a variant peptide, and notably
seven of these were instances in which the corresponding wildtype peptide was already a high-affinity binder (Supplementary
Table S2, C2WT variants and C5WT variants with allele 0101). To
correlate the experimentally measured MHC II affinities with the
algorithm’s binary prediction of peptide binding/nonbinding,
an experimental binding threshold was set at IC50 ≤ 10 μmol/l,
i.e., counting all strong, moderate, and weak binders as defined
above. Given this experimental threshold and an EpiMatrix prediction threshold of 5%, the protein design process yielded a 69%
positive prediction rate across all eight alleles (Supplementary
Table S2). Overall, we observed a 10% false-positive rate and a
21% false-negative rate, similar to those we have reported previously.37–39 At the level of individual peptides, EpiSweep efficiently
identified both high affinity MHC-binders and disruptive mutations, realizing a 37.5% success rate in ablating binding and/or
reducing affinity by more than 10-fold.
For each of the stage 2 variants that expressed as originally
designed, a categorical immunoreactivity score was obtained by
summing the number of strong, moderate, and weak MHC binders among each protein’s component peptides (5 peptides • 8 MHC
alleles = 40 possible interactions per protein). Wild type LSTCAT possessed 11 strong, 4 moderate, and 4 weak binding interactions. As
predicted by the Episcore design parameter (Supplementary Table
S1), immunoreactivity generally decreased across the panel of
variants from F2 to F8 (Figure 2f). Variant F8a in particular exhibited dramatically reduced immunoreactivity, disrupting 10 of 11
strong binders from wild-type LST. At a more moderate mutational
load, variant F4a eliminated three strong binders and manifested
an overall reduction of five binding interactions. Given their strong
performance during preliminary in vitro characterization, these two
deimmunized candidates were selected for more detailed functional and immunogenicity analysis.

© 2015 The American Society of Gene & Cell Therapy

Stage 3: stability and antibacterial activity of lead candidates
Variants F4a and F8a were expressed, purified, and characterized in
biological duplicate. In addition to our own recombinant wild type
LST,32 LST was obtained from a commercial supplier and analyzed
in parallel. The apparent melting temperatures of both F4a and F8a
were consistent with values obtained during preliminary testing,
but their specific rates of bacterial lysis were found to be somewhat higher upon more rigorous analysis (Table 1). Importantly,
the deimmunized variants were equivalent to or better than commercially sourced LST in both assays. The enzymes’ antibacterial
activities were further quantified by assessing minimal inhibitory
concentration (MIC) towards four strains of S. aureus. The F4a MIC
for strain SA113 was equivalent to that of wild type and commercial
LST, and it was within a single 2-fold serial dilution for three clinical isolates, including MRSA strain 3425-3. Variant F8a also retained
good bactericidal/bacteriostatic activity, preventing outgrowth of
all four strains at 200 ng/ml (~7 nmol/l) or less. Given the fact that
the LSTCAT variants encoded four or eight mutations, respectively,
their high levels of anti-staphylococcal activity were striking.
In vivo efficacy and immunogenicity of lead candidates
To assess antibacterial activities in a more clinically relevant fashion,
we employed a murine lung infection model using an S. aureus clinical isolate. Mice were infected with live bacteria via oropharyngeal
aspiration, and one hour later they were treated via the same route
with a solution containing 2.5 μg of wild type LST, variant F4a, or
variant F8a. Twenty-four hours post infection, mice were sacrificed,
lungs were harvested, and viable bacterial counts were determined
by plating serial dilutions of lung homogenate. All three enzymes
yielded a statistically significant 10-fold reduction in bacterial burden relative to a saline buffer control (one-way analysis of variance
P = 0.007, Tukey post hoc test), but there was no significant difference between the three treatments (Figure 3a). Thus, the deimmunized candidates retained wild type efficacy in the infected and
inflamed lung environment.
In vivo immunogenicity was evaluated using NOD/SCID/γc-/- mice
that had been surgically humanized with human immune cells, liver
tissue, and thymus tissue (BLT mice). Following transplantation of
human tissues at 6 weeks of age, BLT mice were allowed to mature
and develop circulating repertoires of human B and T cells. At 14
weeks posttransplantation, mice were divided into three groups of
four each and immunized subcutaneously with 100 ug of wild-type
LST, F4a, or F8a in adjuvant. Thirteen days post immunization, mice
were sacrificed, splenocytes were harvested and pooled for each
group, and the pooled cells were subjected to ex vivo restimulation

Molecular Therapy — Methods & Clinical Development (2015) 15021
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Figure 3 In vivo efficacy and immunogenicity analysis. (a) Bacterial burden in the lungs of C57Bl/6 mice following infection with S. aureus and treatment
with wild type LST (red), variant F4a (dark blue), variant F8a (light blue), or a PBS control (black). Shown are mean values and standard deviations (n = 6
per group). (b) BLT mice (all humanized from a single donor) were immunized subcutaneously with either wild type LST, variant F4a, or variant F8a,
and splenocytes were harvested and restimulated ex vivo with the same protein or DMSO. Proliferation was measured as uptake of tritiated thymidine.
Shown are mean values and standard deviations (n = 4 per group, pooled and measured in triplicate). (c) Transgenic DR4 mice were immunized with
multiple subcutaneous injections of wild-type LST. Following the final boost, mice were allowed to recover for 20 weeks, divided into two groups, and
rechallenged with either wild type LST or variant F4a. Splenocytes were harvested and restimulated ex vivo with the rechallenge protein or DMSO, and
proliferation was measured as uptake of tritiated thymidine. Shown are mean values and standard deviations (n = 5 per group, pooled and measured
in triplicate). Statistical significance was assessed by one-way analysis of variance (panel a) or two-way analysis of variance (panels b and c). *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001.

with their cognate proteins. Cell proliferation was measured by tritiated thymidine uptake at 72 hours, and the stimulation index (protein versus DMSO proliferative response) was 1.6-fold for wild-type
LST (Figure 3b). While this stimulation index is lower than the twofold to threefold cutoff sometimes used in experiments with peripheral blood mononuclear cells taken directly from human subjects,
it bears noting that T cells from humanized mice are widely known
to exhibit impaired function. In particular, humanized mouse splenocytes yield poor ex vivo proliferative responses (e.g., twofold
stimulation index) even to potent stimulatory agents such as phytohaemagglutinin, ionomycin-PMA, keyhole limpet hemocyanin,
and anti-CD3/anti-CD28 antibody cocktails.40,41 Thus, the significant
(P = 0.0005, two-way analysis of variance) 1.6-fold stimulation index
observed here with splenocytes from mice immunized with wild
type LST is a reasonable indicator of an antigen specific immune
response, particularly given the fact that the mice of the current
study received only a single immunization. Relative to the wild type
LST immunized group, pooled splenocytes from F4a and F8a immunized mice exhibited significantly reduced proliferation (Figure 3b).
After background subtraction, F4a pooled cells showed a 50%
reduced response and F8a pooled cells a 65% reduced response.
In addition to inherent immunogenicity in the context of a naive
immune system, we also considered the extent to which a deimmunized protein might evade an established memory response
directed against the wild type LST sequence. Due to the long timeframe of such a study and the short lifespan of BLT mice, we elected
to assess the memory response in transgenic DR4 mice. This homozygous strain bears a chimeric class II MHC derived from murine signaling domains and the peptide binding domains of human HLA
DRA and DRB1*0401.42 This stable transgenic model has a normal,
healthy lifespan enabling extended studies, yet it manifests human
antigen presentation specificity. To establish an anti-LST immune
response, 10 DR4 mice were immunized and repeatedly boosted
with sub-cutaneous injections of wild type LST. Nineteen weeks
after the final boost, mice were divided into two groups of five
each such that each group exhibited similar average antibody titers
Molecular Therapy — Methods & Clinical Development (2015) 15021

(Supplementary Figure S4). Mice were then rechallenged with either
100 μg wild-type LST or 100 μg variant F4a. Thirteen days later, splenocytes were harvested, pooled for each group, and subjected to
ex vivo restimulation with the cognate protein from the final rechallenge. Similar to the results in the BLT mice, ex vivo restimulation
of DR4 splenocytes with wild type LST yielded a 1.8-fold stimulation index (Figure 3c). It bears noting that similarly small stimulation
indices in DR2, DR3, and DQ8 transgenic mice have been shown to
correlate with antigen specific immune responses.43 Thus, the significant (P = 0.0002, two-way analysis of variance) 1
 .8-fold stimulation
index seen here was a reasonable indicator of an anti-drug immune
response. In contrast to mice rechallenged with wild-type LST,
pooled splenocytes from the F4a rechallenge group exhibited no
detectable proliferation above background levels (Figure 3c). Thus,
immune cells primed to recognize wild type LST exhibited reduced
activity upon rechallenge with F4a, suggesting that the deimmunized variant effectively evaded the memory response directed
against the wild type enzyme.
DISCUSSION
LST is a potent bacteriolytic enzyme and a promising candidate for
combating S. aureus infections. However, its inherent immunogenicity poses a barrier to clinical translation. Prior studies sought to
shield LST from the immune system via conjugation with polyethylene glycol (PEGylation).44 While PEGylation reduced LST immunoreactivity and elongated serum half-life, it was ultimately found that
covalent coupling to PEG inactivated the enzyme; residual activity
in PEGylated samples was due to LST that had been noncovalently
and reversibly associated with the polymer.15 Here, we have taken
an alternative approach to mitigating LST immunogenicity, employing a structure-based deimmunization algorithm to design variants
having reduced T cell epitope content yet high levels of antibacterial activity. Importantly, neither an LST x-ray crystal structure nor an
NMR structure was available, and we therefore built a model based
on the structure of the homologous enzyme LytM.29 Leveraging
this molecular model and a Pareto optimal deimmunization
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methodology, we were able to employ high mutational loads to
simultaneously redesign as many as five broadly distributed epi
tope clusters in the LST catalytic domain.
The most recent advances in lytic enzyme biotherapies include
construction of synthetic antibacterial enzymes based on chimeragenesis of modular lysin domains.13,20–26 We anticipated that a
deimmunized LST catalytic domain would prove useful as a fusion
partner to a wide variety of cell wall targeting entities, and we therefore focused our deimmunization efforts on LSTCAT, leaving the LSTBD
cell wall binding domain in its native form. Interestingly, we found
that deimmunization of the catalytic domain was sufficient to suppress the cellular immune response against full length fusion proteins that bore the native LSTBD sequence. We therefore speculate
that immunodominant LST epitopes are localized predominantly
to the catalytic domain, although a rigorous test of this hypothesis
awaits more detailed experimental analyses of the phenotype and
function of cells that proliferate in response to various constructs.
Regardless, mutations targeted to three of five (in the case of F4a) or
five of five (in the case of F8a) putative epitope clusters in the catalytic domain produced marked reductions in global immunogenicity, as measured by ex vivo proliferative response of humanized
murine splenocytes following in vivo immunization with full length
fusion proteins. At the same time, both variants exhibited wild-type
efficacy in a murine lung infection model, a highly relevant system
given the prevalence of S. aureus in both hospital and community
acquired pneumonias.2 Taken as a whole, these results show that
the EpiSweep algorithm efficiently identified mutations and combinations of mutations that suppressed LST immunogenic potential while maintaining high level therapeutic activity. Should the
enzymes’ ability to evade immune cell surveillance ultimately translate into suppressed antidrug antibody responses, one key impediment to LST clinical development will have been addressed. More
generally, we expect that a similar strategy could be employed with
other bacteriolytic drug candidates, many of which are known to
elicit an undesirable immune response in preclinical models.13
Therapeutic enzymes’ mechanisms of action are fundamentally
grounded in reaction catalysis, and the inherent complexity of their
sequence-structure-function relationships may render them particularly sensitive to disruption by molecular manipulations. As a result,
there are currently only six enzymes that have been successfully
engineered by T cell epitope deletion.37,38,45–51 The work described
here represents an important contribution to this space. First, the
threat of drug-resistant bacterial infections is driving growing interest in antibacterial enzymes, and this report is the first and currently
only example of a bacteriolytic biocatalyst deimmunized via T cell
epitope deletion. Second, and more generally, this work serves as
a preliminary validation of an efficient and effective computationally driven deimmunization process that is broadly applicable and
might enable deimmunization of other challenging biotherapeutic
targets. To be sure, humanized mouse models have limitations, and
the success of protein deimmunization must ultimately be measured in the clinic. Nevertheless, the results of EpiSweep deimmunization efforts with both LST and P99 beta-lactamase52 suggest that
the methodology holds great promise as a general tool for accelerating biotherapeutic deimmunization and development.
MATERIALS AND METHODS
Reagents and media
Primers were ordered with standard desalting from IDT Technologies
(Coralville, IA). Commercial lysostaphin, SYPRO Orange 5000x Protein
Stain, and crystal violet dye were purchased from Sigma (St Louis, MO).
All enzymes were obtained from New England BioLabs (Ipswich, MA),
© 2015 The American Society of Gene & Cell Therapy

and all reagents from VWR Scientific (Philadelphia, PA), unless otherwise
noted. Peptides derived from the LST catalytic domain were ordered from
GenScript (Piscataway, NJ), and were greater than 85% pure. MHC-II DR
molecules were purchased from Benaroya Research Institute (Seattle, WA),
anti-MHC-II-DR antibody from Biolegend (San Diego, CA), and DELFIA

Eu-labeled Streptavidin was from PerkinElmer (Boston, MA).

Murine model studies
The protocols for animal infection, immunization, and treatment were
approved by the Institutional Animal Care and Use Committee of Dartmouth
College (Hanover, NH), in accordance with the Association for the Assessment
and Accreditation of Laboratory Animal Care Guidelines. All efforts were
made to minimize animal suffering. All in vivo studies used recombinant wild
type LST that had been produced and purified in house, and differed from
variants F4a and F8a by only the deimmunizing mutations.

Plasmids and strains
P. pastoris strain GS115 and expression vector pPIC9 were from Invitrogen
(Grand Island, NY). S. aureus strains SA113 and S. aureus subsp. aureus (ATCC
25923) were obtained from the American Type Culture Collection (Manassas,
VA). Other clinical isolates of S. aureus (methicillin sensitive strains 6445 and
3425-1, and MRSA strain 3425-3) were the kind gift of Dr Ambrose Cheung
(Dartmouth, Hanover, NH).

Homology modeling
An LSTCAT structural model was constructed using three LytM structures as
templates (1QWY:A, 2B0P:A, and 2B44:A). Two hundred and fifty models
were constructed using MODELLER (Ver. 9.11; ref. 53) and the best model
was selected according to the DOPE potential.54 The templateless region at
24 PLGINGG was separately modeled using FREAD,55 which identified 180
PRGEEGG in 1GMN:A as the best match. The modeled loop structure was
grafted on, and the entire model was minimized using TINKER56 against
AMBER99sb57 with GB/SA.58 The aglycosylated wild type (125 NPT) was modeled by applying in silico mutations to the original model using Scwrl4,59 followed by energy re-minimization.

Epitope prediction
Epitopes were predicted by the EpiMatrix pocket profile method.31
Considered epitopes were limited to those in the top 5% of predicted binders against MHC II alleles DRB1*0101, 0301, 0401, 0701, 0801, 1101, 1301,
and 1501, which are broadly representative of global populations.36

Stage 1 allowed mutations
A total of 10,000 homologs to LSTCAT were collected by running PSI-BLAST60
(3 iterations, e-value <0.001). These sequences were filtered to remove those
with >50% gaps or <35% sequence identity to the wild-type. A diverse set
of 218 representative sequences was subselected so as to have at most 90%
sequence identity to each other. Allowed mutations were those predicted
to delete at least one putative epitope while appearing as frequently as
expected in terms of a background probability distribution.61 Additional filters excluded mutations to/from Pro and Cys, mutations involving active site
residues (32H, 36D, 82H, 113H, and 115H), and mutations previously found
to be detrimental (T43D, S50D, N121D, and L135S).

Computational deimmunization
EpiSweep integrates epitope prediction and molecular mechanics energy
evaluation in order to simultaneously reduce epitope content while maintaining stability and function. It employs an optimization algorithm that
identifies all designs making optimal trade-offs between these criteria
(the Pareto frontier) at a specified mutational load; it can be iterated to
identify successively near-optimal frontiers. Here, EpiSweep was applied
as previously described,27 though using the EpiMatrix epitope predictor as
discussed above. Mutations were restricted to those specified in the deimmunization prior, though all side-chains were allowed to change rotameric
conformation in the search for low energy enzyme designs predicted to
maintain the parental enzyme’s antibacterial activity. Molecular mechanics
energies (a proxy for stability and thereby maintenance of function) were
computed according to AMBER62 as implemented under the open source
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protein design software OSPREY.63 For each stage and each mutational load
from 2 to 8, the Pareto frontier designs were supplemented with designs
comprising 19 successive near-optimal frontiers.
Stage 2 lead variants were selected for a combination of factors including mutational load, minimized energy, and epitope score. All designs were
energy minimized following the same protocol described in Homology
Modeling section (all-atom minimization under AMBER99sb with GB/SA via
the Tinker package). Designs were chosen across the epitope score range
from 24 to 36 at intervals of 2 (compared to wild-type at 50). A total of 14
designs were selected for experimental analysis (Supplementary Table S1).

Cloning of LST single point mutants
Genes encoding LST single point mutants were synthesized by splice overlap extension PCR with synthetic oligonucleotides (Supplementary Table S3)
and an optimized synthetic gene encoding the S126P aglycosylated protein
backbone.32 All PCR reactions were performed using Phusion® High-Fidelity
DNA polymerase. The lysostaphin gene harboring the desired mutations
was digested with EcoRI and XhoI, and ligated into the pPIC9 plasmid using
T4 DNA ligase. The end product of ligation was the lysostaphin gene fused
to the alpha mating factor secretion signal from Saccharomyces cerevisiae.
The plasmid was transformed into E. coli DH5α electrocompetent cells
[F- ɸ80lacZΔM15Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 ( rK− mK+ ) phoA
supE44 λ- thi-1 gyrA96 relA1]. Clones were evaluated for the presence of lysostaphin gene using Syn_F and Syn_R primers and sent for DNA sequencing
to confirm the presence of mutations.

Cloning of LST integrated designs
Lysostaphin variants were synthesized with standard desalting as 432 bp
long gBlocks® gene fragments by IDT Technologies (Coralville, IA). To prepare
the pPIC9 plasmid for insertion of synthesized genes, a silent mutation was
introduced into the lysostaphin linker (residues 135–136) to accommodate a
cutting site for the restriction enzyme AflII. To introduce the necessary mutations, splice overlap extension PCR was used with primers AflII_F and AflII_R
(Supplementary Table S3). The synthetic genes were digested with XhoI and
AflII restriction enzymes, and ligated in similarly digested pPIC9 plasmid
using T4 DNA ligase. The resulting plasmid was transformed into E. coli DH5α
electrocompetent cells and the resulting clones were sequenced to confirm
the presence of mutations.

LST expression and purification
Following sequence confirmation, purified plasmids were digested with
SacI High-Fidelity restriction enzyme prior to electroporation into P. pastoris
strain GS115. The resulting transformants were grown on MD plates (1.34%
yeast nitrogen base (YNB), 0.000004% biotin, 2% dextrose, and 1% agar). For
expression studies, P. pastoris clones were grown in 100 ml BMGY medium
(1% yeast extract, 2% peptone, 1.34% YNB, 0.000004% biotin, 1% glycerol,
100 mmol/l phosphate buffer, pH 6) at 30 °C in 500 ml shake flasks covered
with four layers of cheese cloth for enhanced oxygen flow to the yeast. After
24 hours, cells were centrifuged at 3,000 rpm in a table top centrifuge for 10
minutes. The cells were then resuspended in 100 ml of induction medium
(BMMY: 1% yeast extract, 2% peptone, 1.34% YNB, 0.000004% biotin, 0.5%
methanol, 100 mmol/l phosphate buffer, pH 6) and allowed to grow for the
next 48 hours at 30 °C. At 12-hour intervals, a 1/100 v/v aliquot of 100%
methanol was added to the flasks. After 48 hours of induction, shake flask
culture was centrifuged in a table top centrifuge at 3,000 rpm for 15 minutes.
The resulting supernatant was sterile filtered to remove any yeast cells and
diluted 1:5 with 10 mmol/l KH2PO4 buffer at pH 7.5. Diluted supernatant was
poured over a gravity column packed with 500 µl SP-Sepharose Fast Flow
resin (GE Healthcare; Cleveland, OH). The column was washed with 5 ml of 50
mmol/l NaCl in 10 mmol/l KH2PO4 at pH 7.5. Protein was eluted with 500 µl
aliquots of 200 mmol/l NaCl in 10 mmol/l KH2PO4, pH 7.5. The purity of lysostaphin was determined using SDS–PAGE. The protein concentration was
quantified using ND-1000 Spectrophotometer (NanoDrop Technologies,
Wilmington, DE).

Lytic assay
S. aureus cells were grown either to mid-log or to saturation in tryptic soy
broth (TSB) at 37 °C with shaking. The cells were harvested by centrifugation and washed once in phosphate buffered saline (PBS: 2.7 mmol/l KCl, 1.5
mmol/l KH2PO4, 8.9 mmol/l Na2HPO4, 136.9 mmol/l NaCl, pH 7.4). The assay
Molecular Therapy — Methods & Clinical Development (2015) 15021

was performed in 96-well, black, clear bottom plates from Greiner Bio-One
(Monroe, NC). The final reaction volume (250 µl in PBS) consisted of 10 µl of
P. pastoris culture supernatant (or 200 ng of purified protein), S. aureus cells
at OD600 = 1.5, and 5 µmol/l SYTOX Green (Thermo Fisher Scientific; Waltham,
MA). Data was collected using SpectraMax Gemini Fluorescence Microplate
Reader (Molecular Devices, Sunnyvale, CA) using an excitation/emission
of 504/523 nm, and rates were determined from the slope of the steepest
linear portion of the trace. For the assays performed using P. pastoris culture supernatant, the amount of protein used in each assay was quantified
from SDS–PAGE using Quantity Tools from Image Lab 5.1 software (Bio-Rad
Laboratories, Hercules, CA) (note that in some cases values were extrapolated from the explicitly measured standard curve).

MIC assay
The MICs of wild type LST and deimmunized variants were determined by
adding twofold serial dilutions of enzymes into wells of a polypropylene
96-well plate (Costar 3879) containing ~40,000 S. aureus (strains SA113, 6445,
3425-1, or 3425-3) cells in Muller Hinton II broth (BD) supplemented with 2%
NaCl and 0.1% bovine serum albumin, yielding a total volume of 100 µl. Plates
were grown overnight at 37 °C with shaking at 900 rpm on an Orbit P4 orbital
shaker (Labnet, Edison, NJ). The inhibitory activity of purified lysostaphin was
determined by the concentration of enzyme that prevented visible bacterial
outgrowth. The assay was performed in triplicate for each enzyme.

Thermostability assay
The relative thermostability of the LST variants was determined by differential scanning fluorimetry, as previously described.64 Briefly, proteins and
SYPRO Orange were diluted in PBS (final concentrations of 100 µg/ml and 5×
in 20 µl reaction volume, respectively), and fluorescence was quantified at
1-degree increments from 25 to 94 °C using an Applied Biosystems ABI 7500
fast real-time PCR system. The reactions were performed using PCR Plates
for Fast Thermocyclers (VWR, Radnor, PA). Fluorescence was quantified using
the preset TAMRA parameters. Melting temperatures were determined by
data analysis with the “DSF Analysis v3.0.xlsx” Excel sheet (ftp://ftp.sgc.
ox.ac.uk/pub/biophysics/) and GraphPad Prism v.6.02 software (GraphPad
Software, La Jolla, CA).

MHC binding assays
MHC II competition binding assays were performed using a 384-well
high-throughput assay as previously described.34 Binding assays were performed for the eight alleles: DRB1*0101, 0301, 0401, 0701, 0801, 1101, 1301,
and 1501. Briefly, 100 nmol/l biotinylated control peptides consisting of
known peptide antigens for each MHC II allele were incubated in polypropylene 384-well plates with 50 nmol/l purified recombinant MHC II protein
and serial dilutions of LST or variant peptide fragments (100 μmol/l to 10
nmol/l). Peptide-MHC II complexes were captured from equilibrated solutions using the conformation specific anti-HLA-DR antibody L243 coated on
high binding ELISA plates. Bound control peptide was quantified using the
DELFIA streptavidin-Europium conjugate and time resolved fluorescence
(SpectraMax Gemini Fluorescence Microplate Reader).

Murine lung infection model
Overnight LB cultures of S. aureus strain ATCC 25923 were pelleted, washed
twice with PBS, and resuspended to give 108–109 colony-forming units (CFU)
in 40 μl of PBS. The actual inoculum was determined by serial dilution of the
input bacterial suspension on LB agar (Difco), followed by incubation at 37
°C for 24 hours. Adult female C57BL/6J mice (age, 8 to 12 weeks; Jackson
Laboratories, Detroit, MI) were anesthetized briefly with isoflurane and inoculated with 40 μl of bacterial suspension via oropharyngeal aspiration. At 1
hour postinfection, a second 40 μl PBS inoculation containing either 2.5 μg
wild-type LST, 2.5 μg variant F4a, 2.5 μg variant F8a, or a blank control. At
24 hours postinfection, mice were sacrificed and lungs were excised, placed
into 1 ml of cold PBS, and homogenized. Viable bacterial counts in the lung
homogenate were determined by plating serial dilutions onto LB agar, followed by incubation at 37 °C for 24 hours.

BLT murine immunogenicity studies
BLT mice were constructed by surgical transplantation of human bone
marrow, liver, and thymus tissues into NOD/SCID/γc-/- mice (Dartmouth
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Transgenics & Genetic Constructs Shared Resource) as described in
detail elsewhere.65 All animals were humanized using tissue from a single
DRB1*0101/DRB1*0701 heterozygous donor. Mice used experimentally had
human lymphocytes as a minimum of 25% of their total peripheral blood
leukocytes. Fourteen weeks post engraftment, 12 female BLT mice were
divided into 3 groups of 4 each and immunized with a single 50 μl subcutaneous injection of 100 μg wild type LST, 100 μg variant F4a, or 100 μg variant
F8a in complete Freund’s adjuvant (CFA). Two weeks following the immunization, mice were sacrificed and splenocytes were harvested and pooled for
each group. Pooled splenocytes (5 × 105/well) were plated in triplicate into
96-well plates with medium containing 5% fetal calf serum, l-glutamine,
antibiotics, and a final concentration of 10 μg/ml LST or variants (or 1%
DMSO as a control). After 72 hours of incubation, wells were pulsed with
1 μCi of [3H]thymidine (Dupont NEN, Boston, MA) and harvested 6 hours
later onto Unifilter 96-well GF/C plates for assessment of thymidine incorporation by scintillation counting (Packard MicroSant NXT counter). Serum
from immunized mice was assayed by ELISA for anti-lysostaphin IgM and
IgG antibody titers, but no significant anti-lysostaphin antibody signal could
be detected in either wild type or variant immunized groups. This lack of a
significant humoral immune response to protein antigens is a well-known
limitation in BLT mice.66

Transgenic DR4 murine immunogenicity studies
Twelve female 6–8-week-old DR4 transgenic mice (Abb Knockout/Transgenic
HLA-DR4;
B6.129S2-H2-Ab1tm1GruTg(HLA-DRA/H2-Ea,HLA-DRB1*0401/
H2-Eb)1Kito; Taconic Farms, Germantown, NY) were divided into four groups
of three each and immunized with 50 μl subcutaneous injections of wild-type
LST using one of the following four schemes: (i) initial immunization with 100
μg enzyme in CFA, followed by 100 μg boosts in incomplete Freund’s adjuvant
(IFA) on days 14 and 28; (ii) initial immunization with 20 μg enzyme in CFA,
followed by 20 μg boosts in IFA on days 14 and 28; (iii) initial immunization
with 100 μg enzyme in PBS buffer, followed by 100 μg boosts in PBS buffer
on days 7, 14, 21, and 28; (iv) initial immunization with 20 μg enzyme in PBS
buffer, followed by 20 μg boosts in PBS buffer on days 7, 14, 21, and 28. Serum
IgG antibody titers against wild-type LST were measured on days 13, 20, 27,
34, and 62. Five weeks after the final boost, all 12 mice exhibited equivalent
maximum ELISA signals at a 1:40 serum dilution and all signals were within
20% at a 1:160 dilution (Supplementary Figure S5). Mice were housed without
further manipulation until week 23 of the study, at which time serum IgG antibody titers were again measured and mice were divided into two experimental arms having equivalent average antibody titers (Supplementary Figure S4).
Note that during the week 9 to week 23 recovery period, two mice (the lowest
titer 100 μg no adjuvant and one of the high titer 100 μg adjuvant) began
suffering hair loss, weight loss, and reduced mobility and were sacrificed as
per the IACUC approved protocol. At week 24, one arm was rechallenged with
100 μg wild-type LST in IFA and the other arm with 100 μg variant F4a in IFC.
At week 26, mice were sacrificed and splenocytes were harvested and pooled
for each group. Proliferation assays were conducted as described above. Antilysostaphin antibody titers remained high at the end of the 19-week washout period just prior to the final restimulation (average EC50 at week 24 was
between 1:2,000 and 1:4,000 serum dilution; see Supplementary Figure S4a).
Thus, the memory immune response could not be readily quantified using
antibody titers, and instead the ex vivo proliferative response of mouse splenocytes was used to assess the memory immune response against wild type
LST and the F4a variant.
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